Updated from 7:33 a.m. ET, Tuesday, July 25.
S&P 500 futures added 0.27%, Dow Jones Industrial Average futures were up 0.51%, and Nasdaq futures climbed 0.12%.
Alphabet breezed past analysts' earnings estimates and reported a double-digit increase in sales. The parent of Google earned $5.01 a share over its second quarter, 58 cents higher than consensus. Revenue surged 21% to $26.01 billion and exceeded targets by $410 million.
However, shares fell 2.8% in premarket trading after the company hinted that rising costs could slow profit margin improvements. The company's total traffic acquisition costs increased to $5.091 billion and now represent 22% of Google's advertising revenue.
Jim Cramer and the AAP team said investors are worried about click metrics. For the quarter, aggregate paid clicks increased 52% year over year and 12% sequentially, with a majority of the growth stemming from the Google Properties division. However, aggregate cost per click declined for another quarter, in total declining 23% year over year and 6% sequentially.
"Overall, we are encouraged by the strong quarter despite the discouraging click trend. We believe GOOGL can be successful with its diversification away from advertising, but we understand the business represents the heart of its business and the process will take time," said Cramer and the AAP team.
Eli Lilly topped second-quarter earnings and sales estimates. The drugmaker earned an adjusted $1.11 a share, 6 cents above expectations. Revenue increased 8% to $5.82 billion, beating consensus of $5.59 billion. For the full year, Eli Lilly anticipates adjusted earnings of $4.10 to $4.20 a share and revenue of $22 billion to $22.5 billion.
Shares were slightly lower, though, after the company announced that a new clinical study for its treatment of rheumatoid arthritis is needed before the Food and Drug Administration can move the drug toward market approval. The treatment is a joint project with Incyte Corp. The new study will delay a resubmission for a new drug application until after 2017.
Fellow drugmaker Biogen Inc. (BIIB - Get Report) climbed more than 5% in premarket trading after a better-than-expected quarter. Adjusted earnings of $5.04 a share came in far higher than $4.37 consensus. Revenue of $3.08 billion exceeded estimates of $2.81 billion. Biogen increased its full-year earnings outlook to $20.80 to $21.40 a share, up from previous guidance of $20.45 to $21.25. Biogen said an improved outlook was tied to "faster than anticipated adoption of [muscular atrophy treatment] Spinraza in the U.S."
General Motors Co. (GM - Get Report) was around 1% lower in premarket trading as a retreat from a number of Asian markets weighed on quarterly results. Net income of $1.7 billion fell from $2.9 billion in the same-quarter a year earlier. Around $1.3 billion in net income was tied to losses in its now-sold European operations.
Caterpillar Inc. (CAT - Get Report) surged 5% following a better-than-expected quarter and upbeat outlook. The heavy machinery company earned an adjusted $1.49 a share over its second quarter, far higher than estimates of $1.26. Revenue of $11.3 billion exceeded estimates of $10.9 billion. CEO Jim Umpleby said "construction in China and gas compression in North America were highlights in the quarter. He also said the company was seeing improved demand for construction across most regions.
McDonald's Corp. (MCD - Get Report) jumped 2% on an above-consensus second quarter. Net income of $1.70 a share rose from $1.25 a year earlier and beat analysts' estimates of $1.62. Revenue of $6.05 billion came in higher than an expected $5.96 billion. Global same-store sales increased 6.6%. U.S. same-store sales climbed 3.9%, above estimates of 2.9% growth.
The Federal Reserve will convene Tuesday with an announcement on monetary policy scheduled for Wednesday, July 26. Economists don't expect the central bank to make a change to interest rates, though investors will comb through the Fed statement to discern when the Fed could begin to unwind its balance sheet. Most Fed watchers anticipate that process to begin at the September meeting.
Also on the economic calendar, the S&P Corelogic Case-Shiller home price index for May will be released at 9 a.m. ET, and consumer confidence for July is set for 10 a.m.
Michael Kors Ltd. (KORS) rose 3% in premarket trading after agreeing to buy luxury footwear brand Jimmy Choo PLC (JYMHF) for $1.2 billion. Michael Kors said it would pay 230 pence per share in cash, valuing Jimmy Choo's existing issued and to be issued ordinary share capital at about £896 million ($1.2 billion).
The price represents a 36.5% premium to the closing price of 168.5 pence on April 21, the day before JAB Luxury started a formal sale process for Jimmy Choo.
Following the completion of the acquisition, it's expected that Jimmy Choo will operate as it does today with the same management. Jimmy Choo has about 150 company-operated retail stores, 560 multi-brand stores and more than 60 franchise stores worldwide.
Eat, Drink and Talk Money with Jim Cramer
The evening will start with a screening of Jim's CNBC show Mad Money. Afterwards, Jim will join the party fresh off of the CNBC set to mingle, take photos and answer your investing questions.
Tickets include dinner, drinks and an autographed copy of Jim's book Get Rich Carefully.
Click here for more information or to buy tickets.
Where: Bar San Miguel, 307 Smith St., Brooklyn, N.Y.
When: Tuesday, July 25, 6:30 p.m. to 9 p.m.
More of What's Trending on TheStreet:
- Walmart in Focus Amid 'Horrific' Human Trafficking Incident in Texas That Causes Nine Deaths
- Earnings Are Back With a Vengeance: Cramer's 'Mad Money' Recap (Monday 7/24/17)
- Alphabet Shares Tank as Wall Street Freaks Over Rising Traffic Costs
- Brutal Reactions to Alphabet and Hasbro Results Show You Need to be a Trading Mercenary
- Amazon Tumbling Almost 40% Is Not as Crazy as It Sounds